Akebia Therapeutics IncAKBA
ASignal's systematic analysis rates AKBA as Bearish.
Reflects the latest available analysis · analyzed Aug 22, 2026
The case on AKBA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI indicates deeply oversold conditions (19.5), suggesting potential reversal
- Gross margin remains high at 81.43%, indicating pricing power or efficient production
- Positive free cash flow of $33.62M despite unprofitability
- Cash position strong with $155.55M, providing runway for operations
- MACD below signal line with negative histogram, indicating bearish momentum
- Price trading below both SMA20 and SMA50, confirming downtrend
- Negative revenue growth YoY (-21.4%) and negative operating margin (-5.46%)
- Extremely high debt-to-equity ratio (7.96x) and negative return on equity (-109.38%)
- Forward P/E of -2.75x and negative EV/EBITDA suggest unprofitable valuation
See the full verdict on AKBA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AKBA
Most investors never get a second opinion, let alone several. ASignal runs AKBA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.